林业发展局正在取消60岁以下或更年期后10年内女性更年期激素疗法中的黑盒警告,并列举了风险较低的最新证据。 The FDA is removing black box warnings from menopause hormone therapies for women under 60 or within 10 years of menopause, citing updated evidence of low risk.

林业发展局正在取消绝经激素疗法中的黑盒警告,援引最新科学显示,60岁以下妇女或更年期后10年内,血液凝块和心脏问题等风险很小。 The FDA is removing black box warnings from menopause hormone therapies, citing updated science showing risks like blood clots and heart issues are minimal for women under 60 or within 10 years of menopause. 这一变化在2026年年中生效,反映了对旧研究的重新分析,并承认转基因药物(口服药丸和凝胶)的风险低于口服药丸。 The change, effective by mid-2026, reflects reanalysis of older studies and recognizes that transdermal forms (patches, gels) carry lower risks than oral pills. 先前贴错标签的单质阴道雌激素也豁免。 Topical vaginal estrogen, previously mislabeled, is also exempt. 这一行动旨在减少恐惧驱使的避免现象,并支持基于年龄、时间和健康史的个性化治疗。 The move aims to reduce fear-driven avoidance and support personalized treatment based on age, timing, and health history.